Pre-made Gontivimab benchmark antibody ( Bispecific Single Domains (VH-VH'-VH'), anti-RSV gpF therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Gontivimab benchmark antibody (Bispecific Single Domains (VH-VH’-VH’), anti-RSV gpF therapeutic antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Gontivimab is a monoclonal antibody-derived therapeutic protein (Nanobodies?) (designated as ALX 0171), being developed by Ablynx (a subsidiary of Sanofi) as a once-daily treatment of patients with respiratory syncytial virus (RSV) infections.
| Products Name (INN Index) | Pre-Made Gontivimab biosimilar, Bispecific Single Domains (VH-VH'-VH¡¯): Anti-RSV gpF therapeutic antibody |
|---|---|
| INN Name | Gontivimab |
| Target | RSV gpF |
| Format | Bispecific Single Domains (VH-VH'-VH¡¯) |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | NA |
| VD LC | NA |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Ablynx |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Respiratory syncytial virus infections |
| Development Tech | Nanobody Technology |
| Previous Name | NA |
| Gm Offical Target Name | RSV gpF |
| Package |
